Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONY 1: Albiglutide + Pioglitazone in Type 2 Diabetes
NCT00849056Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2009
- Primary completion
- Nov 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Placebo + Pioglitazone with Albiglutide + Pioglitazone (2 arms). Primary endpoint: Change From Baseline in Glycosylated Hemoglobin at 52 weeks. Started Jan 2009; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00849056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00849056.